Publications by authors named "Melvin Olson"

Claim this Profile
A
Are you implementation ready? An alternative patient and healthcare system-centered model for pharma.
Melvin Skip Olson, Rita Freitas

J Comp Eff Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Value of Integrated Evidence Approaches in Drug Development.
Joseph A DiMasi, Melvin Skip Olson, Zachary Smith, Kenneth A Getz, Gorana Capkun

Ther Innov Regul Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real-World Evidence.
Gorana Capkun, Melvin Skip Olson

Clin Pharmacol Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How pharma can amplify product value with implementation science.
Melvin Skip Olson, Leah L Zullig, Sabina De Geest

J Comp Eff Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of evidence and its role in driving product strategy.
Melvin Skip Olson, Gorana Capkun

J Comp Eff Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Embedding implementation science in the research pipeline.
Leah L Zullig, Connor Drake, Devon K Check, Thekla Brunkert, Mieke Deschodt, Melvin Skip Olson

Transl Behav Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA.
Kayla Engelbrecht, Srinjoy Roy, Gorana Capkun, Kristijan Kahler, Melvin Olson

J Comp Eff Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Swiss Priority Setting on Implementing Medication Adherence Interventions as Part of the European ENABLE COST Action.
Carole Bandiera, Janette Ribaut, Alexandra L Dima, Samuel S Allemann, Kate Molesworth, Melvin Skip Olson

Int J Public Health· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The triple win - implementation science benefits patients, healthcare systems and industry alike.
Melvin Skip Olson, Linda Rootkin

J Comp Eff Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To replicate or not to replicate? Insights and interpretations from a randomized trial duplication initiative.
Melvin Skip Olson, Kristijan H Kahler, Amy E Rudolph

J Comp Eff Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter by Olson et al Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative".
Melvin Skip Olson, Chinmay Deshpande, Kristijan H Kahler

Circulation· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Utilization and Costs in Patients With Migraine Who Have Failed Previous Preventive Treatments.
Lawrence Newman, Pamela Vo, Lujia Zhou, Cristina Lopez Lopez, Andy Cheadle, Melvin Olson

Neurol Clin Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can real-world evidence save pharma US$1 billion per year? A framework for an integrated evidence generation strategy.
Melvin Skip Olson

J Comp Eff Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing an integrated strategy for evidence generation.
Melvin Skip Olson

J Comp Eff Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.
Daisuke Goto, Ya-Chen Tina Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze

Pharmacoeconomics· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis.
Valery Risson, Bhaskar Ghodge, Ian C Bonzani, Jonathan R Korn, Jennie Medin, Melvin Olson

J Med Internet Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Valéry Risson, Deepanshu Saini, Ian Bonzani, Alice Huisman, Melvin Olson

J Med Internet Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies?
William Crown, Jessica Chang, Melvin Olson, Kristijan Kahler, Jason Swindle

J Comp Eff Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT.
Philip N Sambrook, Stuart L Silverman, Jane A Cauley, Chris Recknor, Melvin Olson

Bone· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
Jeroen P Jansen, Gert J D Bergman, Jasper Huels, Melvin Olson

Semin Arthritis Rheum· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis.
Ariane Höer, Cornelia Seidlitz, Holger Gothe, Guido Schiffhorst, Melvin Olson

Patient Prefer Adherence· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jeroen P Jansen, Gert J D Bergman, Jasper Huels, Melvin Olson

Curr Med Res Opin· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
Willemijn M Meijer, Fernie J A Penning-van Beest, Melvin Olson, Ron M C Herings

Curr Med Res Opin· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture outcomes related to persistence and compliance with oral bisphosphonates.
Arlene M Gallagher, Stephan Rietbrock, Melvin Olson, Tjeerd P van Staa

J Bone Miner Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis